Capital & FinanceEvent: September 8, 2026
Moonwalk Biosciences secured a $70 million Series B funding round directed at completing IND-enabling studies for its lead adipose-targeted siRNA candidate MW101 and taking it into first-in-human studies in late 2027.
Published
Signal category
Capital & Finance
Quote
“The $70 million Series B is directed at three things. First, completing the IND-enabling studies for MW101, our lead adipose-targeted siRNA candidate for obesity, and taking it into first-in-human studies in late 2027”
— Moonwalk Biosciences team
Company
Moonwalk Biosciences
Pioneering novel therapeutics in adipose biology and tissue, driven by deep genetic and epigenetic insights
- Industry
- Biotechnology Research
- Location
- South San Francisco, US
- Company size
- 21 employees
Moonwalk Biosciences is pioneering novel therapeutics in adipose biology and tissue, driven by deep genetic and epigenetic evidence and insights. It utilizes its discovery platform to identify novel targets involved in obesity and cardiometabolic disease, and is advancing an early stage pipeline of therapeutic candidates.
Founded 2022